Company Overview - Xenon Pharmaceuticals (XENE) shares have increased by approximately 8.7% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is essential for understanding the key drivers behind this performance [1] Earnings Estimates - Fresh estimates for Xenon Pharmaceuticals have remained flat over the past month [2] VGM Scores - The company has a poor Growth Score of F, a Momentum Score of B, and a Value Score of F, resulting in an aggregate VGM Score of F [3] Outlook - Xenon Pharmaceuticals holds a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the upcoming months [4] Industry Comparison - Xenon Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry, where Celldex Therapeutics (CLDX) has seen a gain of 6.6% over the past month [5] - Celldex reported revenues of $0.69 million for the last quarter, reflecting a year-over-year increase of 331.3% [5] - For the current quarter, Celldex is projected to report a loss of $0.86 per share, a decrease of 59.3% from the previous year [6]
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?